Supernus Pharmaceuticals, Inc.
SUPN· Nasdaq
SUPNSupernus Pharmaceuticals, Inc.
Source filing unavailable
| Metric | Q3 2012 | Q3 2011 |
|---|---|---|
| Revenue | $91.00K | $11.00K |
| Net Income | -$13.48M | -$9.73M |
| EPS Diluted | -$0.55 | -$6.90 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
